NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: GeoVax Third Quarter 2025 Financial Results and Corporate Update
TL;DR
GeoVax's upcoming financial results and business update provide investors key insights into the company's competitive position in vaccine and cancer therapy development.
GeoVax will release Q3 2025 financial results on November 13, followed by a detailed conference call with registration and webcast access procedures.
GeoVax's vaccine development for immunocompromised patients and cancer therapies represents progress toward better healthcare outcomes for vulnerable populations worldwide.
GeoVax is advancing multiple clinical trials including a novel COVID-19 vaccine and oncolytic therapy while planning a direct Phase 3 Mpox vaccine trial.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs will report its financial results for the quarter ended September 30, 2025, and provide a business update on November 13, 2025, including details about their clinical development programs.
The results will be released after the close of U.S. markets on Thursday, November 13, 2025, with a conference call following at 4:30 p.m. ET.
Participants can register in advance at https://edge.media-server.com/mmc/p/u86rmdmb/ or access the live audio webcast via the 'Events & Presentations' section of GeoVax's Investor Relations website at www.geovax.com/investors.
GeoVax's lead COVID-19 program is GEO-CM04S1, a next-generation vaccine currently in three Phase 2 clinical trials being evaluated as a primary vaccine for immunocompromised patients and as a booster for various patient populations.
GeoVax is developing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers.
GeoVax is developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials.
Yes, an archive of the webcast will be available on the Company's website approximately two hours after the conclusion of the call and will remain available for at least 90 days.
For more information about the current status of clinical trials and other updates, visit GeoVax's website at www.geovax.com.
GeoVax Labs is a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, with a strong IP portfolio holding worldwide rights for its technologies and products.
Curated from NewMediaWire
